6R-BH4 ( DrugBank: 6R-BH4 )

3 diseases

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	1
124	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	1
240	Phenylketonuria	1

86. Pulmonary arterial hypertension

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00435331 (ClinicalTrials.gov)	March 2008	12/2/2007	6R-BH4 Pulmonary Arterial Hypertension Study	A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of 6R-BH4 in Subjects With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: sapropterin dihydrochloride (6R-BH4)	Vanderbilt University	National Institutes of Health (NIH);BioMarin Pharmaceutical	Completed	18 Years	N/A	Both	14	Phase 1	United States

Clinical trials : 12 / Drugs : 14 - (DrugBank : 5) / Drug target genes : 3 - Drug target pathways : 11

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004370-55-IT (EUCTR)	14/12/2007	11/12/2007	Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4	Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4	CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulthood and leading in some to severe motor disability with pseudobulbar palsy and dementia of the subcortical type MedDRA version: 9.1;Level: HLGT;Classification code 10008804;Term: Chromosomal abnormalities and abnormal gene carriers	Product Name: Phenoptin Product Code: 6R-BH4 INN or Proposed INN: sapropterin	AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)	NULL	Not Recruiting			Female: yes Male: yes			Italy

Clinical trials : 143 / Drugs : 90 - (DrugBank : 10) / Drug target gene : 1 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00104247 (ClinicalTrials.gov)	March 2005	24/2/2005	Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels	Phenylketonurias	Drug: sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin	BioMarin Pharmaceutical	NULL	Completed	8 Years	N/A	All	89	Phase 3	United States